Contribution of Canine Detection in the Diagnostic Strategy of High-risk Prostate Cancer (Prostate-K9-Detect)

Trial Title: Contribution of Canine Detection in the Diagnostic Strategy of High-risk Prostate Cancer (Prostate-K9-Detect)

NCT ID: NCT05558735

Condition: High-risk Prostate Cancer

Conditions: Official terms:
Prostatic Neoplasms

Conditions: Keywords:
prostate cancer
canine detection
the dog's sense of smell

Study type: Observational

Overall status: Recruiting

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Other
Intervention name: urine collection
Description: urine collection as part of the care and usual follow-up in the context of suspected prostate cancer
Arm group label: case group
Arm group label: control group

Intervention type: Other
Intervention name: canine detection
Description: urine sample will be placed in a detection cone to be sniffed by 6 trained dogs
Arm group label: case group
Arm group label: control group

Summary: The sense of smell allows both humans and dogs to carry out a chemo-sensory analysis of their environment. Volatile organic compounds enter the nasal cavities and bind to receptors in the nasal mucosa. Neuroepithelium cells perform chemoelectric transduction of olfactory information. The latter is supported by one of the fibers of the olfactory nerve which crosses the cribriform plate of the ethmoid to arrive in the olfactory bulb of the brain. Incorporating this information can lead to behavioral responses. The dog has a sense of smell 100,000 times more sensitive than humans, it is able to detect one particle among 1 trillion. The use of detection dogs involves learning the behavioral response to an olfactory stimulus. Prostate cancer represents 25% of male cancers, it is the second deadliest cancer in France with 10,000 deaths per year. Diagnosis of prostate cancer requires a Prostate Specific Antigen (PSA) blood test and a digital rectal examination. In the event of an abnormality in one of these parameters, a prostate MRI is indicated, supplemented by prostate biopsies in the event of an abnormal MRI. However, one situation remains open to discussion: what should be done when faced with a normal MRI despite an abnormal PSA level or digital rectal examination? In this situation and according to current recommendations, the practitioner has the choice between performing prostate biopsies, i.e. an invasive procedure with a high risk of being negative, and simple monitoring, this time with the risk of missing the diagnosis of prostate cancer. Several studies have shown the effectiveness of dogs in detecting very specific volatile organic compounds. Can the investigators train them to detect the catabolites of prostate tumours?

Detailed description: "The purpose of this study is to validate the diagnostic aid performance of canine detection of high-risk prostate cancers (Gleason score 7 or more) by comparing it to prostate MRI with respect to the results of biopsies of the prostate, then to integrate this test into the current diagnostic strategy for prostate cancer. We will carry out a descriptive observational prospective case-control study at the Bichat-Claude Bernard and Henri Mondor hospitals (France) in routine care in adult patients suspected of prostate cancer and having an indication for the realization of a urine sample, an MRI prostate cancer and prostate biopsies. The patient journey will be as follows : During the initial visit (V1), patients suspected of prostate cancer (pathological digital rectal examination, PSA > 4) are informed about the study. They can entrust their non-objection to participate in the study now, or return during a new visit (V2) after a reflection period of 2 to 6 weeks. Each patient completed a clinical information questionnaire. A 60 ml urine sample is taken, part of which is used to perform the ECBU necessary for performing prostate biopsies. The remainder of the sample is used for research. The next visit (V3) is that of performing prostate biopsies, which provide the diagnosis of certainty on the presence or absence of prostate cancer. In the meantime, the patient performed an MRI of the prostate. All of these interventions are part of the usual management of patients suspected of prostate cancer. This visit is followed by the comparison of the results of canine detection and prostate MRI with the results of prostate biopsies. The last visit (V4) is a one-year follow-up visit. A new PSA assay and a digital rectal examination will be performed as part of the usual care. The patients included in our study require a urine sample as part of their therapeutic management. Part of this urine will be collected for our study, it will be frozen and then transported to the veterinary school of Maisons-Alfort. Our research is divided into 2 phases: - The validation phase, consisting of evaluating the diagnostic aid performance of canine olfaction for the diagnosis of prostate cancer in comparison to prostate MRI. - The last phase of clinical interest, aimed at integrating canine olfaction into the current diagnostic strategy for prostate cancer, in particular in the case of negative MRI. The sensitivity of canine olfactory detection will be calculated by dividing the number of patients marked by dogs among the patients diagnosed with high-risk prostate cancer from the biopsy. The sensitivity of detection by MRI will be calculated by dividing the number of patients for whom the MRI indicated the presence of high-risk prostate cancer among the patients diagnosed with high-risk prostate cancer from the biopsy. The 95% confidence intervals will be calculated using Jeffrey's method. The two calculated sensitivities will be compared using McNemar's statistical test. The specificity of canine olfactory detection will be calculated by dividing the number of patients not marked by dogs among the patients who did not have high-risk prostate cancers diagnosed from the biopsy. The specificity of detection by MRI will be calculated by dividing the number of patients for whom the MRI did not indicate the presence of high-risk prostate cancer among the patients whose biopsy did not indicate the presence of high-risk prostate. The 95% confidence intervals will be calculated using Jeffrey's method. The two calculated specificities will be compared using McNemar's statistical test. The concordance assessment scale quantified by Kappa from Landis and Koch will be used to assess the degree of concordance between the two methods (MRI, canine detection) and the biopsy. This study will: - Assess the diagnostic capacity of canine detection of prostate cancer in the event of a negative MRI. - To validate a diagnostic score for prostate cancer including canine detection. - Identify effluvia in the urine characteristic of prostate cancer. - Assess the link between the PSA blood level and the concentration of volatile organic compounds in the urine. - Evaluate the influence of subjects' lifestyle on the diagnostic capacity of canine detection of prostate cancer. - Evaluate the influence of the grade of severity of prostate cancer on the diagnostic capacity of prostate cancer of canine detection. The study respects the measures put in place to deal with the COVID-19 epidemic."

Criteria for eligibility:

Study pop:
Adult male with a positive biopsy (Gleason score greater than or equal to 7)

Sampling method: Probability Sample
Criteria:
"Inclusion criteria : - Older than 18 years old - Requiring the realization of a collection of urine from the framework of their care - Requiring a PSA blood test, prostate MRI and prostate biopsies in the framework of their care Exclusion criteria : - Absence of signed informed consent - People who do not speak French - Persons whose general condition does not allow to participate in the study - Protected populations: under guardianship or under curatorship - Persons deprived of their liberty by a judicial or administrative decision - Persons receiving care psychiatric - Absence of affiliation to a pension scheme social Security"

Gender: Male

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: Hopital Bichat - Claude-Bernard

Address:
City: Paris
Zip: 75018
Country: France

Status: Recruiting

Contact:
Last name: Hermieu Jean-François, Surgeon

Phone: 0140257103

Phone ext: 33
Email: jean-françois.hermieu@aphp.fr

Contact backup:
Last name: de la Taille Alexandre, Surgeon

Phone: 0149812554

Phone ext: 33
Email: alexandre.de-la-taille@aphp.fr

Start date: November 2, 2022

Completion date: December 2025

Lead sponsor:
Agency: Assistance Publique - Hôpitaux de Paris
Agency class: Other

Source: Assistance Publique - Hôpitaux de Paris

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05558735